Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients

International Urology and Nephrology

Volumn 44, Issue 5, 2012, Pages 1441-1449

  Oleniuc, Mihaela ^a   Schiller, Adalbert ^a,b,c   Secara, Irina ^a   Onofriescu, Mihai ^a   Hogas, Simona ^a   Apetrii, Mugurel ^a   Siriopol, Dimitrie ^a   Covic, Adrian ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c Emergency Clinical Hospital   (Romania)

Author keywords

Advanced glycation end products; Cardiovascular disease; Chronic kidney disease; Metabolic stress; Skin autofluorescence

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PARATHYROID HORMONE;

ADULT; AGE; ANURIA; ARTICLE; AUTOFLUORESCENCE; BIOACCUMULATION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEMODIAFILTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARATHYROID HORMONE BLOOD LEVEL; PERIPHERAL VASCULAR DISEASE; PERITONEAL DIALYSIS; POPULATION RESEARCH; SKIN AUTOFLUORESCENCE; TISSUE LEVEL;

ADULT; AGE FACTORS; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OPTICAL IMAGING; PERITONEAL DIALYSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SKIN; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 84867770642     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-011-0097-5     Document Type: Article

References (29)

1. Meerwarldt R, Links T, Graaff R et al (2005) Simple noninvasive measurement of skin autofluorescence. Ann N Y Acad Sci 1043:290
2. Lutgers HL, Graaff R, Links TP et al (2006) Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 29:2654-2659
3. Meerwaldt R, Lutgers HL, Links TP et al (2007) Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30:107-112
4. Tanaka K, Katoh T, Asai J et al (2010) Relationship of skinautofluorescence to cardiovascular disease in Japanese hemodialysis patients. Ther Apher Dial 14:334-340
5. Meerwaldt R, Hartog JWL, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans ROB, Smit AJ (2005) Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 16:3687-3693
6. Aronson Det al (2003) Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 21:3-12
7. Shoji T, Emoto M, Shinohara K et al (2001) Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 12:2117-2124
8. Foley RN, Parfrey PS, Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9(suppl 12):S16-S23
9. Mulder DJ, van Haelst PL, Graaff R, Smit AJ, Gans ROB, Zijlstra F (2005) Skin autofluorescence is an independent marker for acute myocardial infarction. Circulation 112(17): II-371
10. McIntyre NJ, Chesterton LJ, John SG, Jefferies HJ, Burton JO, Taal MW, Fluck RJ, McIntyre CW (2010) Tissueadvanced glycation end product concentration in dialysis patients. Clin J Am Soc Nephrol 5:51-55
11. Meerwaldt R, Hartog JW, Graaff R et al (2007) Skin auto fluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis
12. Meerwaldt R, Hartog JWL, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans ROB, Smit AJ (2005) Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products predicts mortality in hemodialysis patients. J Am Soc Nephrol 16: 3687-3693
13. Koetsier M, Lutgers HL, de Jonge C, Links TP, Smit AJ, Graaff R (2010) Reference values of skin autofluorescence. Diabetes Technol Ther 12(5):399-403
14. Locatelli F, Canaud B, Eckardt KU et al (2003) Oxidative stress in endstage renal disease: an emerging threat to patient outcome. Nephrol Dial Transpl 18:1272-1280
15. Miyata T, de Strihou C, Ueda Y et al (2002) Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 13:2478-2487
16. Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands JL, Smit A (2008) The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol 7:29
17. Tessitore N, Lapolla A, Arico CN et al. Hemodialysis techniques and advanced glycation end products. In: D'Angelo A, Favaro S, Gambaro G (eds). Advanced glycation end products in nephrology
18. van de Kerkhof J, Schalkwijk CG, Konings CJ, Cheriex EC, van der Sande FM, Scheffer PG, ter Wee PM, Leunissen KM, Kooman JP (2004) Nepsilon- (carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients. Nephrol Dial Transpl 19(4):910-916
19. Kalousov'a M, Zima T, Tesǎr V et al (2002) Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients. Blood Purif 20:531-536
20. Fagugli RM, Vanholder R, De Smet R et al (2001) Advanced glycation end products: specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis. Int J Artif Organs 24:256-262
21. Inagi R, Miyata T (1999) Oxidative protein damage with carbohydrates and lipids in uremia. Carbonyl stress Blood Purif 17:95-98
22. Affinito P, Palomba S, Sorrentino C, Di Carlo C, Bifulco G, Arienzo MP, Nappi C (1999) Effects of postmenopausal hypoestrogenism on skin collagen. Maturitas 33:239-247
23. Gerrits EG, Smit AJ, Bilo HJ (2009) AGEs, autofluorescence and renal function. Nephrol Dial Transpl 24:710-713
24. Lutgers HL, Gerrits EG, Graaff R, Lins TP, Sluiter WJ, Gans RO, Bilo HJ, Smit AJ (2007) Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 52:789-797
25. Gerrits EG, Smit AJ, Bilo HJG (2009) AGEs, autofluorescence and renal function. Nephrol Dial Transpl 24:710-713
26. Go AS, Chertow GM, Fan D et al (2004) Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med 351:1296-1305
27. Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, Smit AJ (2007) Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30:107-112
28. McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW (2011) Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clin J Am Soc Nephrol, 2011 Sept 1 [Epub]
29. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele DS (1997) Implication of an increased oxidative stress in the formation of advanced glycation endproducts in patients with end-stage renal failure. Kidney Int 51:1170-1181